Article
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients.
Oncotarget - 1 Nov 2016
Bocchia Monica, Galimberti Sara, Aprile Lara, Sicuranza Anna, Gozzini Antonella, Santilli Francesca, Abruzzese Elisabetta, Baratè Claudia, Scappini Barbara, Fontanelli Giulia, Trawinska Monika Malgorzata, Defina Marzia, Gozzetti Alessandro, Bosi Alberto, Petrini Mario, Puccetti Luca
Abstract excerpt
Several reports described an increased risk of cardiovascular (CV) events, mainly atherothrombotic, in Chronic Myeloid Leukemia (CML) patients receiving nilotinib. However, the underlying mechanism remains elusive. The objective of the current cross-sectional retrospective study is to address a potential correlation between Tyrosine Kinase Inhibitors (TKIs) treatment and CV events. One hundred and 10 chronic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.